Sucampo Pharmaceuticals (SCMP) Sees IPO Pricing Between $14-16 Per Share
SCMP Hot Sheet
EPS Growth %: +140.0%
Sucampo Pharmaceuticals (Nasdaq: SCMP) filed an amended statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $69 million. The Company currently expect the initial public offering price per share of common stock will be between $14.00 and $16.00. The company plans to list on the Nasdaq under the symbol "SCMP".
The offering is being made through Cowen and Company, CIBC World Market and Leerink Swann & Company.
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body.
The offering is being made through Cowen and Company, CIBC World Market and Leerink Swann & Company.
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body.
You May Also Be Interested In
- Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD)
- Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C)
- TRIA Beauty (TRIA) Postponses IPO, Cites Market Conditions
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
